Fate Therapeutics (NASDAQ:FATE) Releases Earnings Results, Beats Expectations By $0.12 EPS

Fate Therapeutics (NASDAQ:FATE – Get Free Report) released its earnings results on Monday. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.12, MarketWatch Earnings reports. Fate Therapeutics had a negative return on equity of 36.63% and a negative net margin of 253.30%. The firm […]

Related Keywords

Canada ,Bahram Valamehr ,Voya Investment Management ,Nuveen Asset Management ,Barclays Plc ,Wells Fargo Company ,Redmile Group Llc ,Fate Therapeutics Inc ,Royal Bank ,Fate Therapeutics Company Profile ,Fate Therapeutics ,Get Free Report ,Marketwatch Earnings ,Director Redmile Group ,Investment Management ,Asset Management ,Howard Capital Management ,Fate Therapeutics Daily ,